Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess clemastine as a remyelinating agent in patients
with relapsing forms of multiple sclerosis. The study will also evaluate the tolerability of
clemastine, originally approved as first-generation antihistamine, in patients with multiple
sclerosis. Study procedures will include assessments for evidence of remyelination in the
anterior visual pathway and in the brain using electrophysiologic techniques and magnetic
resonance imaging. The study will also assess the robustness and stability of this clinical
effect in patients taking clemastine for up to 3 months. Patients in this study can remain on
their standard disease modifying treatment during the course of the study. However, patients
cannot participate in any other investigational new drug research study concurrently.